Clinical Trials
Open
Accrual
5%
SWOG Clinical Trial Number
S1702
A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis
Status Notes
This study is active for patient participation effective 3/8/18 at 2:00 p.m. Eastern.
Research Committee(s)
Myeloma
Activated
03-08-2018
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA8153
Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Status Notes
This study is open to accrual effective February 8, 2018.
Research Committee(s)
Genitourinary Cancer
Activated
02-08-2018
Open
Phase
II
Accrual
34%
SWOG Clinical Trial Number
S1400K
A PHASE II STUDY OF ABBV-399 (PROCESS II) IN PATIENTS WITH C-MET POSITIVE STAGE IV OR RECURRENT SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
Status Notes
Effective on 2/5/18 at 2:00 pm PST, S1400K will be activated.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
Research Committee(s)
Lung Cancer
Activated
02-05-2018
Open
Accrual
2%
SWOG Clinical Trial Number
S1612
A Randomized Phase II/III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia Age 60 or Older
Research Committee(s)
Leukemia
Activated
12-22-2017
Open
Accrual
0%
SWOG Clinical Trial Number
S1619
A Feasibility Trial of Neoadjuvant Cisplatin - Pemetrexed - Atezolizumab with Adjuvant Maintenance Atezolizumab in Resectable Malignant Pleural Mesothelioma
Status Notes
This study is open to accrual effective November 3, 2017 at 2:00 p.m. Eastern.
Research Committee(s)
Lung Cancer
Activated
11-03-2017
ClinicalTrials.gov Registry Number
NCT03228537
Open
Phase
II
Accrual
5%
SWOG Clinical Trial Number
S1613
A Randomized Phase II Study of Pertuzumab and Trastuzumab (TP) compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 Amplification
Status Notes
Effective 10/09/2017 at 2pm Eastern, S1613 will be active for accrual.
Research Committee(s)
Gastrointestinal Cancer
Activated
10-09-2017